176
|
Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 2003; 38:99-103. [PMID: 12844097 DOI: 10.1016/s0741-5214(03)00129-0] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE Platelet activation was assessed in patients with peripheral arterial disease compared with healthy control subjects. METHODS This prospective comparative study included 100 subjects: 40 consecutive patients with intermittent claudication, 20 consecutive patients with critical ischemia and tissue loss, and 40 healthy control subjects. Whole blood flow cytometric analysis was performed to determine resting and stimulated platelet P-selectin expression and resting and stimulated platelet fibrinogen binding. Results are presented as platelet percentage and also as mean fluorescence intensity. RESULTS P-selectin expression was significantly increased in patients with intermittent claudication (median, 0.85%; range, 0.31%-4.77%; P =.023) and critical ischemia (median, 1.11%; range, 0.2%-3.26%; P =.028) compared with control subjects (median, 0.59%; range, 0.16%-4.58%). The percentage of platelets binding fibrinogen was also significantly higher in patients with intermittent claudication (median, 2.89%; range, 1.08%-9.59%; P <.001) compared with control subjects (median, 1.57%; range, 0.17%-10.7%). There was no significant difference in percentage of platelet fibrinogen binding between control subjects and patients with critical ischemia. Fibrinogen binding by stimulated platelets was significantly diminished in patients with critical limb ischemia compared with control subjects (67.2% vs 77.9%; P =.006). CONCLUSIONS Platelet activation is increased in patients with peripheral arterial disease, suggesting an underlying prothrombotic state. Platelets from patients with critical limb ischemia are less responsive to in vitro stimulation.
Collapse
|
177
|
Petrie K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, Zelent A. The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 2003; 278:16059-72. [PMID: 12590135 DOI: 10.1074/jbc.m212935200] [Citation(s) in RCA: 113] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Histone deacetylases (HDACs) perform an important function in transcriptional regulation by modifying the core histones of the nucleosome. We have now fully characterized a new member of the Class II HDAC family, HDAC9. The enzyme contains a conserved deacetylase domain, represses reporter activity when recruited to a promoter, and utilizes histones H3 and H4 as substrates in vitro and in vivo. HDAC9 is expressed in a tissue-specific pattern that partially overlaps that of HDAC4. Within the human hematopoietic system, expression of HDAC9 is biased toward cells of monocytic and lymphoid lineages. The HDAC9 gene encodes multiple protein isoforms, some of which display distinct cellular localization patterns. For example, full-length HDAC9 is localized in the nucleus, but the isoform lacking the region encoded by exon 7 is in the cytoplasm. HDAC9 interacts and co-localizes in vivo with a number of transcriptional repressors and co-repressors, including TEL and N-CoR, whose functions have been implicated in the pathogenesis of hematological malignancies. These results suggest that HDAC9 plays a role in hematopoiesis; its deregulated expression may be associated with some human cancers.
Collapse
|
178
|
Jalali GR, Martineau M, Ford AM, Greaves M, Stevens RF, Harrison CJ. A unique variant of ETV6/AML1 fusion in a child with acute lymphoblastic leukemia. Leukemia 2003; 17:993-5. [PMID: 12750722 DOI: 10.1038/sj.leu.2402873] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
179
|
Xia T, Greaves M, Turta A, Ayasse C. THAI—A ‘Short-Distance Displacement’ In Situ Combustion Process for the Recovery and Upgrading of Heavy Oil. Chem Eng Res Des 2003. [DOI: 10.1205/02638760360596847] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
180
|
Skinner J, Mee TJ, Blackwell RP, Maslanyj MP, Simpson J, Allen SG, Day NE, Cheng KK, Gilman E, Williams D, Cartwright R, Craft A, Birch JM, Eden OB, McKinney PA, Deacon J, Peto J, Beral V, Roman E, Elwood P, Alexander FE, Mott M, Chilvers CED, Muir K, Doll R, Taylor CM, Greaves M, Goodhead D, Fry FA, Adams G, Law G. Exposure to power frequency electric fields and the risk of childhood cancer in the UK. Br J Cancer 2002; 87:1257-66. [PMID: 12439715 PMCID: PMC2408894 DOI: 10.1038/sj.bjc.6600602] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2002] [Revised: 08/16/2002] [Accepted: 08/30/2002] [Indexed: 11/08/2022] Open
Abstract
The United Kingdom Childhood Cancer Study, a population-based case-control study covering the whole of Great Britain, incorporated a pilot study measuring electric fields. Measurements were made in the homes of 473 children who were diagnosed with a malignant neoplasm between 1992 and 1996 and who were aged 0-14 at diagnosis, together with 453 controls matched on age, sex and geographical location. Exposure assessments comprised resultant spot measurements in the child's bedroom and the family living-room. Temporal stability of bedroom fields was investigated through continuous logging of the 48-h vertical component at the child's bedside supported by repeat spot measurements. The principal exposure metric used was the mean of the pillow and bed centre measurements. For the 273 cases and 276 controls with fully validated measures, comparing those with a measured electric field exposure >/=20 V m(-1) to those in a reference category of exposure <10 V m(-1), odds ratios of 1.31 (95% confidence interval 0.68-2.54) for acute lymphoblastic leukaemia, 1.32 (95% confidence interval 0.73-2.39) for total leukaemia, 2.12 (95% confidence interval 0.78-5.78) for central nervous system cancers and 1.26 (95% confidence interval 0.77-2.07) for all malignancies were obtained. When considering the 426 cases and 419 controls with no invalid measures, the corresponding odds ratios were 0.86 (95% confidence interval 0.49-1.51) for acute lymphoblastic leukaemia, 0.93 (95% confidence interval 0.56-1.54) for total leukaemia, 1.43 (95% confidence interval 0.68-3.02) for central nervous system cancers and 0.90 (95% confidence interval 0.59-1.35) for all malignancies. With exposure modelled as a continuous variable, odds ratios for an increase in the principal metric of 10 V m(-1) were close to unity for all disease categories, never differing significantly from one.
Collapse
|
181
|
Abstract
Abstract
The unique operation of the THAI (Toe-to-Heel Air Injection) process, enables very high oil recovery and substantial in situ upgrading. Both thermal upgrading (non-catalytic) and also catalytic upgrading, in which a catalyst is emplaced along the horizontal producer well, were investigated. 3D physical model experiments were conducted on virgin Athabasca tar sand bitumen to investigate dry and wet combustion performance. These results were compared against those from a steamflood test, which was subsequently followed by air injection. Excellent ignition, very stable combustion propagation and thermal upgrading of nearly 10 ° API were achieved using Athabasca tar sand. Additional upgrading was achieved using an in situ catalyst. THAI has the extra advantage that some hydrogen is generated in situ, providing further significant upgrading via hydroconversion. There are also substantial environmental benefits because of the large reductions in sulphur and heavy metals in the produced oil. Furthermore, oil is produced without "displacement delay," immediately ahead of the combustion front. The oil recovery using THAI was greater than 75% OOIP.
Introduction
The world's conventional crude oil production is expected to reach its peak in the second decade of this century and enter a permanent decline phase(1). The composition of the oil barrel is getting heavier, and diluent blending "stop-gaps," assisted by very limited coker upgrading capacity will, eventually, be insufficient to cope with the increasing demand for light oil. Historically, heavy oil trades at a substantial discount to that of premium light crude oil. Therefore, it has lower economic value and also market potential, unless new technology is developed to upgrade it to lighter oil, in an economic manner.
The Athabasca Tar Sand deposit of northeastern Alberta, Canada, is one of the largest reserves of bitumen in the world. These are estimated to be 212.9 ??109 m3 (1,339 ?109 bbl)(2). Although about 10% of the bitumen reserves are mineable, the rest of the Athabasca Tar Sands have to be exploited by in situ recovery technology. A number of in situ oil recovery methods, such as steam assisted gravity drainage (SAGD)(3) and in situ combustion (ISC)(4, 5), have been extensively studied, both in the laboratory and in field tests.
In situ combustion (ISC) is a thermal EOR method, in which a small fraction of the oil (or coke) in the oil layer is burned in order to mobilize the unburned fraction. Due to the strong exothermic oxidation reactions between hydrocarbon (or coke) and oxygen, the temperature of the oil-bearing matrix in the combustion zone is 500 to 700 °C, which is much higher than in steam flood processes (150 to 250 °C). High temperatures are very favourable for tar sands and heavy oil reservoirs, because not only is the oil viscosity reduced by several orders of magnitude, but the heavy residue is also thermally cracked to lighter compounds.
Collapse
|
182
|
Taylor GM, Dearden S, Ravetto P, Ayres M, Watson P, Hussain A, Greaves M, Alexander F, Eden OB. Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. Hum Mol Genet 2002; 11:1585-97. [PMID: 12075003 DOI: 10.1093/hmg/11.14.1585] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
In a previous study, we obtained preliminary evidence in a small series of patients (n = 63) suggesting that susceptibility to childhood common acute lymphoblastic leukaemia (c-ALL) was associated with an allele at the HLA-DPB1 locus, DPB1*0201. We have now tested this hypothesis by comparing the frequency of children with leukaemia (n = 982) who typed for specific DPB1 alleles and two groups of non-leukaemic children, one consisting of children with solid tumours, excluding lymphomas (n = 409), the other consisting of normal infants (n = 864). We found that significantly more children with c-ALL and T-ALL, but not pro-B ALL or acute non-ALL typed for DPB1*0201 as compared with children with solid tumours [odds ratio (OR), 95% confidence interval (CI) for c-ALL: 1.76, 1.20-2.56; T-ALL: 1.93, 1.01-3.80] and normal infants (OR, 95% CI for c-ALL: 1.83, 1.34-2.48; T-ALL: 2.00, 1.10-3.82). In childhood c-ALL, significantly more children than those with solid tumours or normal infants typed for DPB1 alleles coding specific polymorphic amino acids lining the antigen-binding site of the DPbeta1*0201 allotypic protein, suggesting that susceptibility to childhood c-ALL may be influenced by DPbeta ABS amino acid polymorphisms shared by DPbeta1*0201 and other DPbeta1 allotypes. These results point to a mechanism of c-ALL susceptibility that involves the presentation of specific antigenic peptides, possibly derived from infectious agents, by DPbeta1*0201-related allotypic proteins, leading to the activation of helper T cells mediating proliferative stress on preleukaemic cells.
Collapse
|
183
|
Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, Hows JM, Navarrete C, Greaves M. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A 2002; 99:8242-7. [PMID: 12048236 PMCID: PMC123052 DOI: 10.1073/pnas.112218799] [Citation(s) in RCA: 418] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Studies on monozygotic twins with concordant leukemia and retrospective scrutiny of neonatal blood spots of patients with leukemia indicate that chromosomal translocations characteristic of pediatric leukemia often arise prenatally, probably as initiating events. The modest concordance rate for leukemia in identical twins ( approximately 5%), protracted latency, and transgenic modeling all suggest that additional postnatal exposure and/or genetic events are required for clinically overt leukemia development. This notion leads to the prediction that chromosome translocations, functional fusion genes, and preleukemic clones should be present in the blood of healthy newborns at a rate that is significantly greater than the cumulative risk of the corresponding leukemia. Using parallel reverse transcriptase-PCR and real-time PCR (Taqman) screening, we find that the common leukemia fusion genes, TEL-AML1 or AML1-ETO, are present in cord bloods at a frequency that is 100-fold greater than the risk of the corresponding leukemia. Single-cell analysis by cell enrichment and immunophenotype/fluorescence in situ hybridization multicolor staining confirmed the presence of translocations in restricted cell types corresponding to the B lymphoid or myeloid lineage of the leukemias that normally harbor these fusion genes. The frequency of positive cells (10(-4) to 10(-3)) indicates substantial clonal expansion of a progenitor population. These data have significant implications for the pathogenesis, natural history, and etiology of childhood leukemia.
Collapse
|
184
|
Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM, Smith MT, Zhang L, Feusner J, Wiencke J, Pritchard-Jones K, Kempski H, Greaves M. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002; 99:3801-5. [PMID: 11986239 DOI: 10.1182/blood.v99.10.3801] [Citation(s) in RCA: 180] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Recent reports have established the prenatal origin of leukemia translocations and resultant fusion genes in some patients, including MLL-AF4 translocations in infants and TEL-AML1 translocations in children. We now report evidence for the prenatal origin of a translocation in childhood acute myeloid leukemia (AML). The t(8;21) AML1-ETO translocations were sequenced at the genomic level in 10 diagnostic leukemia samples from children with available neonatal Guthrie blood spots. Clonotypic genomic AML1-ETO sequences were detected in the Guthrie spots for 5 individuals, providing unambiguous evidence of prenatal origin in these cases. Two of these patients were older than 10 years of age at diagnosis, indicative of a protracted postnatal latency. Three of the patients were assessed for the persistence of genomic fusion sequences in complete clinical remission samples and were found to be positive. These data indicate that t(8;21) in childhood AML can arise in utero, possibly as an initiating event in childhood AML, and may establish a long-lived or stable parental clone that requires additional secondary genetic alterations to cause leukemia.
Collapse
MESH Headings
- Acute Disease
- Child
- Child, Preschool
- Chromosomes, Human, Pair 21
- Chromosomes, Human, Pair 8
- Core Binding Factor Alpha 2 Subunit
- DNA, Neoplasm/analysis
- Humans
- Infant, Newborn
- Leukemia, Myeloid/diagnosis
- Leukemia, Myeloid/drug therapy
- Leukemia, Myeloid/genetics
- Oncogene Proteins, Fusion/genetics
- RUNX1 Translocation Partner 1 Protein
- Remission Induction
- Transcription Factors/genetics
- Translocation, Genetic
Collapse
|
185
|
Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, Greaves M, Vickers MA. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87:779-85. [PMID: 12038776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
DNA samples collected as part of a large population-based case-control study were genotyped to examine the associations of five prothrombotic gene polymorphisms with pre-eclampsia (PE) and gestational hypertension (GH). The polymorphisms studied were: G1691A in Factor V (Factor V Leiden; FVL), prothrombin G20210A, methylenetetrahydrofolate reductase (MTHFR) C677T, plasminogen activator inhibitor-1 4G/5G and the platelet collagen receptor alpha2beta1 C807T. A group of 404 women who developed PE were retrospectively compared with 303 women with GH and 164 control women. The frequency of genotypes did not differ significantly between cases of PE or GH and controls for any of the five polymorphisms studied. We conclude that these prothrombotic genotypes are not associated with the development of PE or GH in our population. The systematic review supports our conclusion, for all but cases of severe disease. which appear to be associated with FVL and, to a lesser extent, MTHFR C677T. There is little value in antenatal screening for prothrombotic polymorphisms to predict the development of pre-eclampsia or gestational hypertension.
Collapse
|
186
|
Ozturk O, Greaves M, Templeton A. Aspirin dilemma. Remodelling the hypothesis from a fertility perspective. Hum Reprod 2002; 17:1146-8. [PMID: 11980730 DOI: 10.1093/humrep/17.5.1146] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Many clinical trials in obstetrics have failed to demonstrate improved outcomes with low-dose aspirin. This is not entirely surprising as prescribing aspirin for compromised tissue perfusion without insight into underlying pathology inevitably leads to suboptimal outcomes. We argue that a mismatch between the aspirin dose and the underlying pathology of altered tissue perfusion is the key factor to this failure. Based on this groundwork, we address the question of how best to optimize the dose of aspirin for use in fertility management, by providing examples from the assisted conception and recurrent miscarriage settings.
Collapse
|
187
|
Abstract
Causal mechanisms in all diseases are diverse and multifactorial, but medical scientists, as pragmatists, inevitably focus on limited or circumscribed components of pathogenetic puzzles. In cancer, epidemiologists have traditionally sought to incriminate exposures; geneticists uncover inherited susceptibility; and molecular biologists deconstruct the proximal mechanisms of cell transformation. Molecular epidemiology promises to deliver new insights in terms of gene-environment interactions. Each of these endeavours has undeniably provided rich dividends and insights into cancer causation, but are these likely to be sufficient as a coherent explanation of our vulnerability to cancer? I suggest that the biological plausibility of causal mechanisms would benefit from a historical, evolutionary perspective. The essential argument is that genes or gene variants and phenotypic traits that were adaptively selected in the past as advantageous now contribute crucially to cancer because of their mismatch with current environmental and social circumstances. The risk attributes of skin pigmentation and some dietary factors in cancer can be plausibly interpreted within this context. A case is made here for a Darwinian perspective on breast and prostate cancers, for which current understanding of causation is limited and contentious.
Collapse
|
188
|
MESH Headings
- Child
- Child, Preschool
- Chromosomes, Human, Pair 12
- Chromosomes, Human, Pair 21
- Genetic Markers
- Genetic Predisposition to Disease
- Humans
- Infant
- Infections/complications
- Infections/immunology
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Myeloid, Acute/therapy
- Oncogene Proteins, Fusion
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Prognosis
- Translocation, Genetic
- Twin Studies as Topic
Collapse
|
189
|
Watson HG, Chee YL, Greaves M. Rare acquired bleeding disorders. REVIEWS IN CLINICAL AND EXPERIMENTAL HEMATOLOGY 2001; 5:405-29; quiz following 431. [PMID: 11844136 DOI: 10.1046/j.1468-0734.2001.00050.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Accurate diagnosis of the cause of bleeding is a prerequisite for determination of the optimal therapeutic response. Clinicians are generally aware of the more prevalent hemorrhagic syndromes but some rare acquired conditions are also of importance. In many of these, inhibitors of coagulation factors or of platelet adhesion/aggregation cause bleeding. These inhibitors are generally, but not always, immunoglobulins. In this review, the less common inhibitors of coagulation and hemostasis, as well as some important but rare nutritional, iatrogenic and disease associated hemorrhagic disorders, are described.
Collapse
|
190
|
Eguchi M, Eguchi-Ishimae M, Seto M, Morishita K, Suzuki K, Ueda R, Ueda K, Kamada N, Greaves M. GPHN, a novel partner gene fused to MLL in a leukemia with t(11;14)(q23;q24). Genes Chromosomes Cancer 2001; 32:212-21. [PMID: 11579461 DOI: 10.1002/gcc.1185] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
We report a novel MLL-associated chromosome translocation t(11;14)(q23;q24) in a child who showed signs of acute undifferentiated leukemia 3 years after intensive chemotherapy that included the topoisomerase-II inhibitor VP 16. Screening of a cDNA library of the patient's leukemic cells showed a novel fusion transcript between MLL and the Gephyrin (GPHN) gene on 14q24. The resulting MLL-GPHN fusion gene encodes MLL AT hook motifs and a DNA methyltransferase homology domain fused to the C-terminal half of Gephyrin, including a presumed tubulin binding site and a domain homologous to the Escherichia coli molybdenum cofactor biosynthesis protein MoeA. Genomic breakpoint analysis showed potential in vitro topoisomerase-II DNA-binding sites spanning the breakpoints in both MLL and GPHN but no flanking sequences that might mediate homologous recombination. This suggests that MLL-GPHN may have been generated by VP 16/topoisomerase-II-induced DNA double-strand breaks, followed by error-prone DNA repair via non-homologous end joining. Gephyrin was originally identified as a submembraneous scaffold protein that anchors and immobilizes postsynaptic membrane neurotransmitter receptors to underlying cytoskeletal elements. It also is reported to bind to phosphatidylinositol 3,4,5-triphosphate binding proteins involved in actin dynamics and downstream signaling and interacts with ATM-related family member RAFT1. Gephyrin domains in the chimeric protein therefore could contribute novel signal sequences or might modify MLL activity by oligomerization or intracellular redistribution.
Collapse
MESH Headings
- Amino Acid Sequence
- Base Sequence
- Carrier Proteins/genetics
- Child, Preschool
- Chromosome Breakage/genetics
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 14/genetics
- Cloning, Molecular
- DNA-Binding Proteins/genetics
- Female
- Histone-Lysine N-Methyltransferase
- Humans
- Leukemia, Monocytic, Acute/genetics
- Membrane Proteins/genetics
- Molecular Sequence Data
- Myeloid-Lymphoid Leukemia Protein
- Oncogene Proteins, Fusion/genetics
- Proto-Oncogenes
- Transcription Factors
- Translocation, Genetic
Collapse
|
191
|
|
192
|
Bodie SL, Ford I, Greaves M, Nixon GF. Thrombin-induced activation of RhoA in platelet shape change. Biochem Biophys Res Commun 2001; 287:71-6. [PMID: 11549255 DOI: 10.1006/bbrc.2001.5547] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Thrombin-induced activation of RhoA and its involvement in the regulation of myosin II light chain(20) phosphorylation (MLC-P) in alpha-toxin permeabilized platelets was investigated. Permeabilized platelets, expressing normal levels of P-selectin, displayed a Ca(2+)-dependent increase in shape change and MLC-P. Thrombin activated RhoA as measured by a rhotekin-binding assay within 30 s of stimulation under conditions of constant [Ca(2+)](i). Under the same conditions and timecourse, thrombin or GTPgammaS induced an increase in MLC-P and platelet shape change which was not dependent on an increase in [Ca(2+)](i). The thrombin- and GTPgammaS-induced MLC-P in constant [Ca(2+)](i) was inhibited by the addition of Y27632, a Rho-kinase inhibitor. This study directly demonstrates that thrombin can activate RhoA in platelets in a timecourse compatible with a role in increasing MLC-P and shape change (not involving an increase in [Ca(2+)](i)). This is also Rho-kinase-dependent.
Collapse
|
193
|
Ford I, Cotter MA, Cameron NE, Greaves M. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism 2001; 50:868-75. [PMID: 11474472 DOI: 10.1053/meta.2001.24914] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Oxidative stress and defective fatty acid metabolism in diabetes may lead to impaired nerve perfusion and contribute to the development of peripheral neuropathy. We studied the effects of 2-week treatments with evening primrose oil (EPO; n = 16) or the antioxidant alpha-lipoic acid (ALA; n = 16) on endoneurial blood flow, nerve conduction parameters, lipids, coagulation, and endothelial factors, in rats with streptozotocin-induced diabetes. Compared with their nondiabetic littermates, untreated diabetic rats had impaired sciatic motor and saphenous sensory nerve-conduction velocity (NCV; P <.001), reduced endoneurial blood flow (P <.001), and increased serum triglycerides (P <.01), cholesterol (P < 0.01), plasma factor VII (P <.0001), and von Willebrand factor (vWF; P <.0001). Plasma fibrinogen and serum high-density lipoprotein concentrations were not significantly different. Treatment with either ALA or EPO effectively corrected the deficits in NCV and endoneurial blood flow. ALA was associated with marked and statistically significant decreases in fibrinogen, factor VII, vWF, and triglycerides (P <.01, paired t tests before v after treatment). In contrast, EPO was associated with significant (P <.05) increases in fibrinogen, factor VII, vWF, triglycerides, and cholesterol and a significant decrease in high-density lipoprotein. Changes in levels of coagulation factors and lipids, qualitatively similar to those found with EPO, were obtained with a diet containing sunflower oil (to control for calorific and lipid content) or with a normal diet alone. Blood glucose and hematocrit levels were not significantly altered by treatments. These data suggest that although both ALA and EPO improve blood flow and nerve function, their actions on vascular factors differ. The marked effects of ALA in lowering lipid and hemostatic risk factors for cardiovascular disease indicate potential antithrombotic and antiatherosclerotic actions that could be of benefit in human diabetes and merit further study.
Collapse
|
194
|
Greaves M. Antiphospholipid syndrome: state of the art with emphasis on laboratory evaluation. HAEMOSTASIS 2001; 30 Suppl 2:16-25. [PMID: 11251337 DOI: 10.1159/000054159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Antiphospholipid antibodies (aPLs) are associated with arterial and venous thrombosis, recurrent pregnancy loss and thrombocytopenia. Although aPLs have not yet been conclusively shown to be causal in thrombosis and miscarriage, they are useful laboratory markers for the antiphospholipid syndrome (APS). The syndrome can complicate another autoimmune disease, most commonly systemic lupus erythematosus, but more often occurs alone -- primary APS. Identification of the syndrome is clinically important because of the risk of recurrent thrombosis and the need for antithrombotic therapy in many cases. Diagnosis and treatment of APS represent significant challenges, however, owing to the protean clinical manifestations and associations, limitations of currently available laboratory tests for aPLs, and the lack of clear evidence-based guidance on optimal management.
Collapse
|
195
|
Varley JM, Attwooll C, White G, McGown G, Thorncroft M, Kelsey AM, Greaves M, Boyle J, Birch JM. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 2001; 20:2647-54. [PMID: 11420676 DOI: 10.1038/sj.onc.1204369] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2000] [Revised: 01/15/2001] [Accepted: 02/12/2001] [Indexed: 11/09/2022]
Abstract
Germline TP53 splicing mutations have been described infrequently (>2%) in the literature, however in a series of 40 patients and families identified by our group in which there are germline TP53 mutations, seven affect splicing (18%). The low figure reported in the literature might reflect the method of mutation detection, which in many studies does not include all splice junctions. These data indicate that a significant proportion of TP53 germline mutations are currently unrecognized. We have carried out detailed studies of the effects of the different mutations on splicing, and see distinct variations in the effects of the same mutation in different patients. Furthermore we have identified the usage of a non-consensus splice donor site in four families with an intron 4 splice donor mutation.
Collapse
|
196
|
Scott JA, Arnold JJ, Currie JM, Broadfoot C, Davidson M, Kelly KF, Graham A, Kirkpatrick JN, Greaves M. No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. Ophthalmologica 2001; 215:217-21. [PMID: 11340395 DOI: 10.1159/000050862] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Factor V:Q506 (factor V Leiden) is associated with venous thrombosis and has been reported to be a risk factor for retinal vein occlusion (RVO). Anticardiolipin antibodies (ACA), also associated with RVO, are a marker for the prothrombotic condition antiphospholipid syndrome, in which antiendothelial antibodies (AECA) are also frequently present. This study reviewed 45 younger patients <or=55 years old (21 with branch, 22 with central and 2 with hemispheric RVO) to examine: (1) the rôle of factor V:Q506 in the pathogenesis of RVO, and (2) the prevalence and titre of ACA and AECA in this group. No patient had the factor V:Q506 mutation indicating no increase in frequency above background. Our data suggest that primary screening for factor V:Q506 is not indicated for young patients with RVO who do not have historical evidence suggesting familial thrombophilia. Twenty-nine patients had low-titre ACA (>10 GPL units); in 6 of these, the titre was >20 GPL units (population reference range = 0-10 GPL units). No patient had antiendothelial cell reactivity. The low-titre ACA may therefore represent a non-specific response to vascular injury.
Collapse
|
197
|
Greaves M, Preston FE. Rebuttal to: oral contraceptives and venous thromboembolism. Thromb Haemost 2001; 85:932-4; author reply 934-6. [PMID: 11372691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
|
198
|
Meiklejohn DJ, Vickers MA, Morrison ER, Dijkhuisen R, Moore I, Urbaniak SJ, Greaves M. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001; 112:621-31. [PMID: 11260063 DOI: 10.1046/j.1365-2141.2001.02620.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Platelet membrane glycoprotein polymorphisms are candidate risk factors for thrombosis, but epidemiological data are conflicting. Thus, demonstration of a genotype-dependent alteration in function is desirable to resolve these inconsistencies. We investigated in vivo platelet activation in acute thrombosis and related this to platelet genotype. Frequencies of the 1b and 2b alleles of the HPA 1a/1b and HPA 2a/2b platelet glycoprotein polymorphisms were determined in 150 (52 men/98 women, mean age 58.3 years) patients with atherothrombotic stroke, and the influence of genotype on markers of platelet activation was assessed. Platelet P-selectin (CD62P) expression and fibrinogen binding was measured using whole blood flow cytometry within 24 h of stroke and 3 months later in 77 patients who provided a repeat blood sample. Results were compared with matched controls. Neither the 1b allele [allele frequency 0.11 vs. 0.13, odds ratio (OR) confidence interval (CI) 0.8 (0.5-1.3)] nor the 2b allele [0.09 vs. 0.07, OR (CI) 1.4 (0.8-2.4)] was significantly over-represented in patients. Increased numbers of activated platelets were found following stroke (acute mean P-selectin expression 0.64% vs. control 0.35%, P < 0.001; acute mean fibrinogen binding 1.6% vs. control 0.9%, P < 0.001). Activation persisted in the convalescent phase (P < 0.001 and P = 0.005 vs. controls for P-selectin and fibrinogen respectively). Expression of P-selectin and fibrinogen was not influenced by either the HPA 1a/1b genotype (P > 0.95 for each marker, Scheffe's test) or the 2a/2b genotype (P > 0.95 for each). Although persisting platelet activation is seen in atherothrombotic stroke, it is independent of HPA 1a/1b and 2a/2b genotypes. These data suggest an underlying prothrombotic state, but do not support the polymorphisms studied as risk factors for thrombotic stroke in this population.
Collapse
|
199
|
Greaves M, Saghr A, Xia T, Turtar A, Ayasse C. THAI-New Air Injection Technology for Heavy Oil Recovery and In Situ Upgrading. ACTA ACUST UNITED AC 2001. [DOI: 10.2118/01-03-03] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Abstract
THAI-"Toe-to-Heel" Air Injection, is a new EOR process, which integrates advanced technology and horizontal well concepts, to achieve a potentially very high recovery of heavy oil. It can also realize very substantial in situ upgrading by thermal cracking, producing upgraded oil to the surface. The process operates in a gravity stabilized manner by restricting drainage to a narrow mobile zone. This causes the flow of mobilized fluids to enter directly into the exposed section of a horizontal production well. The process can be operated on primary production, asnew technology, as a follow-up to existing technologies, or asa co-process where the advantages of high thermal efficiency are equired. This is achieved by concentrating the energy required for oil mobilization, recovery and thermal upgrading in the reservoir. Combined with clean technology design, THAI offerspathway, to future economic success for the heavy oil industry. Three-dimensional, semi-scaled experimental tests on light "Forties Mix" oil (30.7 °CDATA[API), Clair, West of Shetlands medium heavy oil (20.8 °CDATA[API), and heavy Wolf Lake oil (10.95 °CDATA[API) show that a well-controlled, narrow mobile oil zone is created just ahead of the combustion front. The width of this narrow zone depends on the characteristics of the heavy oil at reservoir conditions and the degree to which the very high viscosity of the cold oil seals the horizontal producer well. Well sealing can be augmented by a novel sleeve-back technique, which allows perforated downstream sections of the well to be shut-in. The application of this technique enabled the light oil test to mimic the operation of a heavy oil reservoir using THAI. Very high oil recoveries were achieved in the tests, up to 85﹪ OOIP. During wet in situ combustion (ISC), Wolf Lake oil was upgraded to 20 °CDATA[API, achieving a reduction in the cold oil viscosity from 100,000 mPas to around 50 mPas.
Introduction
Horizontal and multi-lateral wells are being introduced in ever increasing numbers to achieve further gains in reservoir productivity. Two hundred horizontal wells were drilled a decade ago. Now, one company has reported drilling more than 2,100 horizontalwells in North America(1). Advances have also been achieved in the depths drilled, reaching 8,761m(2) and lengths now reaching up to 11 km. Multi-lateral wells, with four or more side-tracks, are not uncommon and offer further optimization gains. Moreover, this technology will accommodate reservoir faults and problems of structural geology as regular design factors so that strategic placement of the well path is achieved. More recently, a new technique to control gas and water production rates by varying the fluid entry points has been successfully tested(3). The most important advantage of horizontal wells is the increase in the reservoir contact area compared to a vertical well. Horizontal wells have created new possibilities for the implementation of advanced IOR methods, especially in thermal recovery.
Collapse
|
200
|
Meiklejohn DJ, Vickers MA, Dijkhuisen R, Greaves M. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001; 32:57-62. [PMID: 11136915 DOI: 10.1161/01.str.32.1.57] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Homocysteine is a proposed causal risk factor for atherosclerosis, but this remains controversial. We measured fasting plasma homocysteine concentrations immediately after atherothrombotic stroke and in the convalescent period to investigate this controversy. METHODS One hundred six patients (59 men and 47 women, mean age 57.2 [25 to 70] and 56.5 [26 to 69] years, respectively) were recruited within 24 hours of admission, and 82 patients were resampled at least 3 months later. Fasting total plasma homocysteine (tHcy) concentrations were measured by high-performance liquid chromatography. RESULTS Median tHcy in the acute phase of stroke was not significantly higher than in matched control subjects (men 9.2 [range 4.4 to 22.8] versus 8.7 [4.9 to 20] micromol/L, P:=0.09, Mann-Whitney U: test; women 8.1 [4.8 to 32.3] versus 7.6 [3.3 to 14.4] micromol/L, P:=0.58). Median plasma concentrations increased significantly in the convalescent period (from 8.5 [4.8 to 19.2] to 10.1 [4.3 to 31.5] micromol/L, P:<0.001, Wilcoxon signed rank test) and were then significantly higher than in control subjects in both men and women (P:=0.03 and 0.05, respectively, Mann-Whitney U: test). This did not appear to be explained by alteration in the known covariates red-cell folate, serum B(12), or creatinine concentrations. CONCLUSIONS Homocysteine concentrations are not elevated after recent atherothrombotic stroke but rise in the convalescent period. These data do not support the hypothesis that raised plasma homocysteine concentrations predate atherothrombotic stroke. Instead, they offer an explanation for the discrepancies between prospective and retrospective studies and suggest that elevated tHcy levels may be caused by the disease process itself.
Collapse
|